Logo_Anaqua-Color.png
Global Law Firm Nixon Peabody Goes Live with Anaqua’s Comprehensive Suite of IP Management Software and Services
06 déc. 2023 02h52 HE | Anaqua
BOSTON, Dec. 06, 2023 (GLOBE NEWSWIRE) -- Anaqua, the leading provider of innovation and intellectual property (IP) management technology today announced that global law firm Nixon Peabody has gone...
Unknown
The Akkermansia Company Found to be ‘First to File’ Patent Application to Treat Obesity Through Oral Use of the Probiotic Akkermansia
05 déc. 2023 09h44 HE | The Akkermansia Company
The Akkermansia Company was found to be the "first to file" a patent application to treat obesity through oral use of the probiotic Akkermansia.
checkpoint.jpg
Checkpoint Therapeutics Strengthens Intellectual Property Protection for Cosibelimab with New U.S. Patent Issuance
05 déc. 2023 08h30 HE | Checkpoint Therapeutics, Inc
Upcoming PDUFA goal date of January 3, 2024 U.S. patent protection for cosibelimab through at least May 2038 WALTHAM, Mass., Dec. 05, 2023 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc....
Copy of FINAL_LOGO_NO_TAG_LINE (4)
Movi Family LLC files Motion to Dismiss Patent Infringement Case For Its Innovative Changing Pad
30 nov. 2023 12h01 HE | Movi Family LLC
Pasadena, Nov. 30, 2023 (GLOBE NEWSWIRE) -- Movi Family LLC (“Movi"), a family-owned baby brand, has filed a Motion to Dismiss a competitor lawsuit baldly alleging design patent and trade dress...
Algernon Logo 1.png
Algernon Pharmaceuticals Receives Notice of Intention to Grant from Chinese Patent Office for Repirinast to Treat NASH and NAFLD
30 nov. 2023 07h00 HE | Algernon Pharmaceuticals
VANCOUVER, British Columbia, Nov. 30, 2023 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (the “Company” or “Algernon”) (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF) a Canadian clinical stage...
Kane Logo Cropped TransBG.png
Kane Biotech Announces Improved Third Quarter 2023 Financial Results
28 nov. 2023 16h05 HE | Kane Biotech Inc.
WINNIPEG, Manitoba, Nov. 28, 2023 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE; OTCQB:KNBIF) (the “Company” or “Kane Biotech”) today announced its third quarter 2023 financial results. Third...
AIMLogo.jpg
AIM ImmunoTech Bolsters Intellectual Property Estate for Ampligen® with Issuance of Two Key U.S. Patents
27 nov. 2023 09h05 HE | AIM ImmunoTech Inc.
Extends certain exclusive U.S. rights to Ampligen for cancer and ME/CFS through 2039 Management discusses patent issuance and what this means in a brief video: here OCALA, Fla., Nov. 27, 2023 ...
EVOK Logo.jpg
Evoke Pharma Announces FDA Orange Book Listing of New GIMOTI Patent
27 nov. 2023 08h30 HE | Evoke Pharma, Inc.
SOLANA BEACH, Calif., Nov. 27, 2023 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with...
Kane Logo Cropped TransBG.png
Kane Biotech to Release Third Quarter 2023 Financial Results on November 28, 2023 – Conference Call to Follow
21 nov. 2023 07h45 HE | Kane Biotech Inc.
WINNIPEG, Manitoba, Nov. 21, 2023 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX- V:KNE; OTCQB:KNBIF) (the “Company” or “Kane Biotech”), a biotechnology company engaged in the research, development and...
EVOK Logo.jpg
United States Patent and Trademark Office (USPTO) Grants Another Formulation Patent Covering GIMOTI
14 nov. 2023 08h30 HE | Evoke Pharma, Inc.
SOLANA BEACH, Calif., Nov. 14, 2023 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with...